PMID- 26477955
OWN - NLM
STAT- MEDLINE
DCOM- 20160706
LR  - 20231111
IS  - 1872-7123 (Electronic)
IS  - 0165-1781 (Print)
IS  - 0165-1781 (Linking)
VI  - 230
IP  - 2
DP  - 2015 Dec 15
TI  - First-episode bipolar disorder is associated with erythrocyte membrane 
      docosahexaenoic acid deficits: Dissociation from clinical response to lithium or 
      quetiapine.
PG  - 447-53
LID - S0165-1781(15)30394-2 [pii]
LID - 10.1016/j.psychres.2015.09.035 [doi]
AB  - Deficits in long-chain omega-3 (LCn-3) fatty acids eicosapentaenoic acid (EPA) 
      and docosahexaenoic acid (DHA) may be associated with the pathophysiology of 
      bipolar disorder. However, LCn-3 fatty acid status at the initial onset of mania 
      and its association with treatment response are not known. Erythrocyte membrane 
      fatty acid composition was determined in first-episode bipolar manic or mixed 
      (n=40) and healthy (n=40) subjects. Mood symptom ratings were obtained with the 
      Young Mania Rating Scale (YMRS) and the Hamilton Depression Rating Scale (HDRS). 
      Erythrocyte fatty acid composition and clinical ratings were also determined 
      within a sub-group of bipolar subjects following 8-week (n=19) or 52-week (n=11) 
      open-label treatment with lithium or quetiapine. At baseline bipolar subjects 
      exhibited significantly lower erythrocyte docosahexaenoic acid (DHA, 22:6n-3) 
      composition compared with healthy subjects (-23%, p<0.0001). EPA (20:5n-3) and 
      docosapentanoic acid (22:5n-3), and LCn-6 fatty acids including arachidonic acid 
      were not different. Following 8- or 52-week treatment with lithium or quetiapine, 
      YMRS and HDRS total scores decreased significantly whereas erythrocyte fatty 
      acids including DHA did not change. These data indicate that selective 
      erythrocyte DHA deficits coincide with the initial onset of manic symptoms, and 
      reductions in mood symptoms following treatment are not mediated by changes in 
      fatty acid status.
CI  - Copyright (c) 2015 Elsevier Ireland Ltd. All rights reserved.
FAU - McNamara, Robert K
AU  - McNamara RK
AD  - Department of Psychiatry and Behavioral Neuroscience, Division of Bipolar 
      Disorders Research, University of Cincinnati College of Medicine, Cincinnati, OH 
      45267, USA. Electronic address: robert.mcnamara@uc.edu.
FAU - Jandacek, Ronald
AU  - Jandacek R
AD  - Department of Pathology, University of Cincinnati, Cincinnati OH 45237, USA.
FAU - Tso, Patrick
AU  - Tso P
AD  - Department of Pathology, University of Cincinnati, Cincinnati OH 45237, USA.
FAU - Blom, Thomas J
AU  - Blom TJ
AD  - Department of Psychiatry and Behavioral Neuroscience, Division of Bipolar 
      Disorders Research, University of Cincinnati College of Medicine, Cincinnati, OH 
      45267, USA.
FAU - Welge, Jeffrey A
AU  - Welge JA
AD  - Department of Psychiatry and Behavioral Neuroscience, Division of Bipolar 
      Disorders Research, University of Cincinnati College of Medicine, Cincinnati, OH 
      45267, USA.
FAU - Strawn, Jeffrey R
AU  - Strawn JR
AD  - Department of Psychiatry and Behavioral Neuroscience, Division of Bipolar 
      Disorders Research, University of Cincinnati College of Medicine, Cincinnati, OH 
      45267, USA.
FAU - Adler, Caleb M
AU  - Adler CM
AD  - Department of Psychiatry and Behavioral Neuroscience, Division of Bipolar 
      Disorders Research, University of Cincinnati College of Medicine, Cincinnati, OH 
      45267, USA.
FAU - DelBello, Melissa P
AU  - DelBello MP
AD  - Department of Psychiatry and Behavioral Neuroscience, Division of Bipolar 
      Disorders Research, University of Cincinnati College of Medicine, Cincinnati, OH 
      45267, USA.
FAU - Strakowski, Stephen M
AU  - Strakowski SM
AD  - Department of Psychiatry and Behavioral Neuroscience, Division of Bipolar 
      Disorders Research, University of Cincinnati College of Medicine, Cincinnati, OH 
      45267, USA.
LA  - eng
GR  - R01 DK097599/DK/NIDDK NIH HHS/United States
GR  - R34 MH083924/MH/NIMH NIH HHS/United States
GR  - DK59630/DK/NIDDK NIH HHS/United States
GR  - P50 MH077138/MH/NIMH NIH HHS/United States
GR  - UL1 TR001425/TR/NCATS NIH HHS/United States
GR  - U24 DK059630/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20151009
PL  - Ireland
TA  - Psychiatry Res
JT  - Psychiatry research
JID - 7911385
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Fatty Acids, Unsaturated)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - 2S3PL1B6UJ (Quetiapine Fumarate)
RN  - 9FN79X2M3F (Lithium)
RN  - AAN7QOV9EA (Eicosapentaenoic Acid)
SB  - IM
MH  - Adolescent
MH  - Antipsychotic Agents/*therapeutic use
MH  - Bipolar Disorder/*blood
MH  - Docosahexaenoic Acids/blood/*deficiency
MH  - Eicosapentaenoic Acid/blood
MH  - Erythrocyte Membrane/*chemistry
MH  - Fatty Acids, Unsaturated/blood
MH  - Female
MH  - Healthy Volunteers
MH  - Humans
MH  - Lithium/*therapeutic use
MH  - Male
MH  - Psychological Tests
MH  - Quetiapine Fumarate/*therapeutic use
MH  - Young Adult
PMC - PMC4655201
MID - NIHMS731263
OTO - NOTNLM
OT  - Arachidonic acid
OT  - Bipolar disorder
OT  - Lithium
OT  - Mania
OT  - Quetiapine
EDAT- 2015/10/20 06:00
MHDA- 2016/07/07 06:00
PMCR- 2016/12/15
CRDT- 2015/10/20 06:00
PHST- 2015/04/23 00:00 [received]
PHST- 2015/08/19 00:00 [revised]
PHST- 2015/09/22 00:00 [accepted]
PHST- 2015/10/20 06:00 [entrez]
PHST- 2015/10/20 06:00 [pubmed]
PHST- 2016/07/07 06:00 [medline]
PHST- 2016/12/15 00:00 [pmc-release]
AID - S0165-1781(15)30394-2 [pii]
AID - 10.1016/j.psychres.2015.09.035 [doi]
PST - ppublish
SO  - Psychiatry Res. 2015 Dec 15;230(2):447-53. doi: 10.1016/j.psychres.2015.09.035. 
      Epub 2015 Oct 9.